P. Sherrill Neff
Angel Investor @ Quaker BioVentures
Merion Station, United States
P. Sherrill Neff is a Series C investor at Quaker BioVentures in Merion Station focused on Health Care and Therapeutics. Founding Partner of Quaker PartnersPreviously: President, COO, and Director, Neose Technologies, a publicly traded life sciences company. Senior VP, Corporate Development, U.S. Healthcare, a leading publicly traded HMO. Managing Director, Investment Banking Division, Alex. Brown & Sons. Corporate Attorney at Morgan, Lewis & Bockius.Board Responsibilities: Cempra Pharmaceuticals, Intact Vascular, Neuronetics, RainDance Technologies, and Regado BiosciencesOther Investment Responsibilities: Achillion Pharmaceuticals, Durata Therapeutics and Horizon PharmaPrior Board Participation: Amicus Therapeutics, Biolex, BioRexis (acquired by Pfizer) and Medmark (acquired by Walgreen Co.), and Optherion.Other: Board of Directors, National Venture Capital Association (NVCA); Board of Directors, Resource Capital Corporation (NYSE:RSO); Chairman, Policy Board, WXPN-FM, listener supported radio from the University of Pennsylvania. Former Chairman, Greater Philadelphia Venture Group; Former President, Pennsylvania Biotechnology Association. Former board member, University City Science Center, Biotechnology Institute, and Vesper Boat Club. Former board member of the following publicly traded companies: Neose Technologies, Jefferson Bank, The Bancorp, and Resource America.Education: B.A. from Wesleyan University and J.D. magna cum laude from the University of Michigan Law School
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries P. Sherrill Neff invests in
Stages P. Sherrill Neff invests in
Countries P. Sherrill Neff invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Pharmaceutical 1 (33%)
Stage
- Series C 1 (33%)
- Series D 1 (33%)
- Post-IPO Equity 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Ourprincipal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system. | $50.1M / Post-IPO Equity / Aug 18, 2010 | ||
| Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronaryintervention. It was founded in 2001 and headquartered in Durham, North Carolina. | $40M / Series D / Dec 17, 2009 | ||
| Regado Biosciences is a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronaryintervention. It was founded in 2001 and headquartered in Durham, North Carolina. | $23M / Series C / Mar 27, 2007 |
Co-Investors
About Quaker BioVentures
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development,from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital.
Quaker BioVentures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brenda D. Gavin
Partner
|
|||
Richard S. Kollender
Partner
|
|||
Adele Oliva
Partner
|
|||
Geeta Vemuri
Partner
|
|||
Ira Lubert
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does P. Sherrill Neff invest in?
P. Sherrill Neff invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series C and Series D stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact P. Sherrill Neff?
Public channels for P. Sherrill Neff include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did P. Sherrill Neff last invest?
The most recent investment recorded for P. Sherrill Neff closed in Aug 2010. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
